https://doi.org/10.55788/942c2d29
“There is no standard second-line treatment for patients with MPM,” explained Dr Li-Anne Douma (Netherlands Cancer Institute - Antoni van Leeuwenhoek, the Netherlands). The current phase 2 study (NCT04287829) evaluated the safety and efficacy of pembrolizumab and lenvatinib in 38 patients with recurrent MPM. The included patients received up to 35 cycles of the combination therapy and objective response rate (ORR) was the primary endpoint of the trial.
The ORR was 58%, exceeding the expectations of the investigators. All of the 22 responses were partial, and all other patients had stable disease at the time of the analysis. Furthermore, ORR by independent central review was 42%.
In total, 13 serious adverse events (AEs) were reported, 76% of the patients required at least 1 dose reduction or discontinued from lenvatinib, and 3 patients discontinued permanently from pembrolizumab. The most common any-grade AEs were fatigue (n=21), hoarseness (n=21), anorexia (n=16), and diarrhoea (n=15). Hypertension was the most common grade 3 AE (n=2) and 2 cases of grade 4 myositis were observed. Dr Douma commented that the safety profile was remarkable but manageable, and that the assessed combination therapy showed the highest in-trial ORR in the second-line treatment of MPM.
- Douma L-A, et al. Pembrolizumab plus lenvatinib in second and third line malignant pleural mesothelioma patients; a single arm phase 2 study (PEMMELA). OA04.06, WCLC 2022, Vienna, Austria, 06–09 August.
Copyright ©2022 Medicom Medical Publishers
Posted on
Previous Article
« Early detection strategies in younger patients with lung cancer are urgently needed Next Article
Talazoparib plus temozolomide appears efficacious in ES-SCLC »
« Early detection strategies in younger patients with lung cancer are urgently needed Next Article
Talazoparib plus temozolomide appears efficacious in ES-SCLC »
Table of Contents: WCLC 2022
Featured articles
IMpower010: First interim OS analysis of adjuvant atezolizumab in NSCLC
Sub-lobar resection as new standard-of-care for cT1aN0 NSCLC?
WCLC 2022 Congress Round-Up
Sugemalimab offers PFS benefits for unresectable NSCLC
First results of sotorasib plus pembrolizumab in KRAS p.G12C-mutated NSCLC
IMpower010: First interim OS analysis of adjuvant atezolizumab in NSCLC
Sub-lobar resection as new standard-of-care for cT1aN0 NSCLC?
NADIM: Risk of progression identified through RNA sequencing
NADIM II: OS benefit of neoadjuvant nivolumab plus chemotherapy in NSCLC
POSEIDON: Novel option for harder-to-treat subgroups of patients with metastatic NSCLC?
First DLL3-targeted therapy shows promise in SCLC
KEYNOTE-604: Very durable responses on pembrolizumab plus EP in SCLC
Talazoparib plus temozolomide appears efficacious in ES-SCLC
Pembrolizumab plus lenvatinib performs well in MPM
Early detection strategies in younger patients with lung cancer are urgently needed
Intensive co-located smoking cessation programme highly effective during lung screening
Do we underestimate the effect of air pollution on lung cancer incidence?
Interventions needed to address sexual health in lung cancer
Related Articles
© 2023 Medicom Medical Publishers. All rights reserved. Terms and Conditions | Privacy Policy